Compare ALLT & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | BCYC |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.0M | 310.7M |
| IPO Year | 2006 | 2019 |
| Metric | ALLT | BCYC |
|---|---|---|
| Price | $7.27 | $4.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $12.40 | ★ $13.90 |
| AVG Volume (30 Days) | 439.7K | ★ 542.3K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.84 | N/A |
| Revenue Next Year | $12.09 | N/A |
| P/E Ratio | $469.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.12 | $3.95 |
| 52 Week High | $11.92 | $9.18 |
| Indicator | ALLT | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 34.52 |
| Support Level | $6.98 | $3.95 |
| Resistance Level | $7.47 | $4.75 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 46.46 | 2.63 |
Allot Ltd is a provider of security and network intelligence solutions for mobile, fixed, and cloud service providers, as well as enterprises. It offers network-based security solutions such as mobile security, DDoS protection, and IoT security, along with network analytics and traffic management. It focuses on expanding its Security-as-a-Service (SECaaS) offerings through the Allot Secure product family, which delivers unified protection for consumers and SMBs across mobile, fixed, and 5G networks. Its Allot Smart solutions enable service providers to analyze and manage network data, optimize performance, reduce costs, and enhance user experience. It has a customer base in Europe, which generates maximum revenue, as well as in Asia and Oceania, the Americas, the Middle East, and Africa.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.